Vitamin K2 + Vit D3 Benefits

• Vitamins D3 and K2 have been shown to support bone mineralization and lower fracture risk*
• Vitamins D3 and K2 studied and reported to play a key role in supporting the cardiovascular system as well as blood sugar balance already within normal levels.*
• Vitamin K2 provides critical cardiovascular protection by helping to activate matrix GLA protein (MGP), an inhibitor of circulatory calcification.*
• Several Studies have shown that both Vitamins D3 and K2 are associated with a stronger immune function and help to balance the inflammatory response.*
• Vitamins D3 and K2 help to support a strong protein matrix for bone mineralization.*
• Vitamins D3 and K2 shown helpful in maintaining adequate blood calcium levels, which help support cellular metabolic processes, and cardiovascular and neuromuscular/neurological function.*
• Vitamins D3 and K2 support the health and elasticity of arterial walls.*

*This has Vit D3 (5,000 IU) – It is Safe to take daily, but make sure you are testing your blood every few months to track your Vitamin D levels and talk to your doctor if you have any concerns or questions.*

The association of MK-7 to vitamin D3 has important osteoinductive effects in relation to bone matrix mineralization through the induction of osteocalcin synthesis and carboxylation. The study shows a synergic effect of the association of MK-7/D3 with a rise of cOC in treated cells.

Studies Overview: VitaMK7: An effective vitamin supplement for all stages of life: See Entire Overview Here

What is vitaMK7 Vitamin K2 (menaquinone-7), is derived from the bio-fermentation process of the Bacillus subtilis ssp natto, without chemical compounds.

The biological activity of MK-7 is strictly linked to its natural, structural all trans configuration. In natural environments, bacteria produce menaquinone-7 only in the trans-form. vitaMK7® is a natural vitamin K2 as MK-7 with a very high level of purity: it contains >99% of all trans. Menaquinone7 (MK-7), the only active form of vitamin K2.

vitaMK7® purity means:

• No contamination from the fermentation process
• No bacterial residues
• No need for calcium addition and crystals
• No need for synthetic or other forms

The purity of vitamin K2 is dual. It is measured by:

The isomeric purity, i.e. the percentage of trans-isomer (the active form of vitamin K2 as MK-7) in the product vs. cis isomer (inactive).

The general purity, i.e. the percentage of substances which are actually vitamin K2 within the product vs. other substances resulting from the manufacturing process.

These “general” impurities are therefore different for natural vitamin K2 from fermentation vs. synthetic vitamin K2.

This formula includes the patented VitaMK7®, a natural vitamin K2 (as MK7) which supports enhanced utilization of calcium in the bloodstream.* It is an all-trans natural menaquinone-7 with the highest bioavailability and longest half-life in the blood.* VitaMK7® is shown in human clinical studies to increase osteocalcin (calcium-binding protein) levels, enhancing the body’s ability to utilize calcium in the bloodstream.* It is also shown to prevent bone loss and promote bone integrity while significantly reducing the incidence of arterial calcification, promoting optimal cardiovascular function.* An in-vitro study shows VitaMK7® inhibits the production of PGE-2, a prostaglandin that acts as a potent stimulator of bone loss.* It is non-GMO and solvent-free and processed under the strictest purity standards.

Although Vitamin K is best known for its role in normal blood clotting function, recent research has revealed Vitamin K's beneficial effects on bone and cardiovascular health. In bone tissue, Vitamin K is critical for the formation of a healthy, strong bone matrix. In fact, bone quality is dependent on the presence of adequate Vitamin K. Vitamin K's role in arterial health revolves around its ability to support proper calcium metabolism in vascular structures. Vitamin K2 is the most biologically active form of vitamin K. It is also the most beneficial for bone integrity, as well as for the support of arterial health.

Vitamin K2 is involved in bone metabolism. Vitamin K2 homologs (menaquinones) are characterized by the number of isoprenoid residues comprising the side chain. Menaquinones are abbreviated MK-n, where n represents the number of isoprenoid side chains. Thus, menaquinone-4 abbreviated MK-4 has 4 isoprene residues in the side chain. Bacteria can produce a range of vitamin K2 forms, including the conversion of K1 to K2 (MK-7) by bacteria in the small intestines. No known toxicity exists for vitamins K1 and K2.*

Vitamin K2 provides major protection from osteoporosis, cardiovascular blockages, and pathological calcification.

Vitamin K's job is to put calcium in the right places and keep it from being deposited in the wrong places. The right places are bones and blood, and the wrong places include calcification of the vessels, bone spurs, and calcification of soft tissues.

Vitamin K was discovered in the 1920's as a fat-soluble factor important in blood coagulation ("K" for coagulation). Vitamin K1 is found in plants and vitamin K2 is found in animals and bacteria, including beneficial probiotic bacteria, aka "good bacteria," from the GI tract. The body can store about a one-month supply of the vitamin. Antibiotics interfere with the growth of healthy intestinal bacteria and as a result, impair vitamin K production. The prescription anticoagulant Warfarin also interferes with the metabolism and function of vitamin K by inhibiting critical enzymes that are involved with the production of coagulation factors. Without this coagulation factors, excessive bleeding can occur.

Vitamin K works by acting as a cofactor in the carboxylation (adding of a carboxyl group C02) via an enzyme (gamma-glutamyl carboxylase), of glutamic acid (a specific amino acid) to form a modification of that amino acid (gamma carboxyglutamic acid) in a variety of critical plasma proteins. Without this step, these plasma proteins will not function in their role of the regulation of calcium concentrations in various tissues.

There are several different types of GCGA proteins including osteocalcin (OC), which is the most abundant GCGA protein in humans and is synthesized in bone; the GCGA protein-containing blood coagulation factors are synthesized in the liver; the matrix GCGA proteins (MGP) are synthesized in the cartilage and in the vessel walls of arteries. 1

According to the Food and Nutrition Board of the National Academy of Sciences National Research Council, the requirements of vitamin K in micrograms (mcg) range from 5 micrograms for infants and up to 80 mcg for adult males and 65 mcg for adult females. 2

When vitamin K is in short supply in the body, these proteins are formed without the GCGA component and are inactive for their intended functions - which play important roles in four different tissue types including 1) liver; 2) bone; 3) cartilage; and 4) arterial vessel walls.

These four tissues are all able to pull vitamin K from the blood. However, the uptake from the liver is much greater for K1 than for other tissues. Very important recent findings indicate that vitamin K2, and not K1 inhibits Warfarin-induced arterial calcification. This research is important for those on Warfarin and has implications for the majority of us who are unaware that we are deficient in this lifesaving nutrient.

Because the liver needs so much vitamin K, this can leave the cartilage and bone GCGA proteins with inadequate levels. Hence the dietary vitamin K requirement for bone and the special requirements for the cardiovascular system and cartilage may not be met even though normal clotting factor production occurs, as this occurs in the liver. Therefore, the requirement to keep the vasculature clear of accumulating calcium and to keep the bones well supplied with calcium may not be adequately supplied. This is why the recent discoveries on the value of vitamin K2 and its recent commercial availability can make a great difference in the lives of millions - probably a majority of the population would benefit.

The FDA's current recommendations for vitamin K dosage are based solely on the liver's requirements alone. It has been identified that a large percentage of the enzymes that do not receive GCGA because of a vitamin K1 or K2 deficiency become unable to mobilize calcium and place it into the bone where it belongs. This GCGA-deficient enzyme is known as undercarboxylated osteocalcin (ucOC). It was found that this occurs in the majority of the healthy adult population indicating subclinical vitamin deficiency in a large portion of the population. 3,4 Though this is subclinical in terms of obvious symptoms, the first symptoms may be osteoporosis or acute coronary disease... the first symptom may even be death.


See Other LifeSource Vitamins Vitamin K Products, Articles, and Studies: Click Here

The results of a vitamin K intervention study have been examined in which both bone mineral density and vascular elasticity were shown to increase. 5 Other studies have demonstrated consistent findings adding to the conclusion that vitamin K1, and preferably, a good amount of vitamin K2, may just be some of the best protection for preventing calcification of the arteries, and for protection against osteoporosis.

Oral anticoagulant medications such as Warfarin or Coumadin, etc., which are the most commonly used anticoagulants, are vitamin K antagonists. Vitamin K may lessen the concentration of the anticoagulants.

Other Benefits of Vitamin K

We have discussed the beneficial effects of vitamin K on bone density, cardiovascular health, and the Syndrome X diseases, however, there are even more benefits to vitamin K supplementation.

Anti-Inflammatory

Further research has demonstrated vitamin K's anti-inflammatory action. As the body ages, levels of the inflammation-promoting cytokine interleukin-6 (IL-6) increase. Once IL-6 becomes out of ba lance with the other cytokines, inflammation accelerates. It has been observed that people with arthritis, Alzheimer's disease, and atherosclerosis have higher levels of IL-6. In a study done by the National Research Institute in Italy, it was shown that subjects with the highest levels of IL-6 were almost twice as likely to develop mobility-related disabilities.

Diabetes

The second highest concentration of vitamin K in the body is in the pancreas, which plays a major role in blood sugar and insulin regulation. In animal studies, Japanese researchers found that when they induced vitamin K deficiency, the test animals developed Type II diabetes. 31

Antioxidant

Research has indicated that vitamin K has antioxidant activity comparable to vitamin E and CoQ10. 32,33 Animal studies have demonstrated complete hepatic (liver) protection from induced oxida tive stress using vitamin K, and was found to be 80% as effective as vitamin E in preventing oxidation.

Alzheimer's

About 25% of the population have a genetic predisposition for developing Alzheimer's disease - they carry the E4 form of the lipoprotein apoE. Interestingly, people who carry this gene have been found to have low levels of vitamin K. Calcification and the development of lesions in blood vessels that feed the brain tissues are believed to be a component of Alzheimer's development. Further research may reveal high-dose vitamin K therapy to be preventive.

Japanese Study on Vitamin K2 & Viral Cirrhosis-Related Liver Cancer

Japanese researchers have recently discovered that vitamin K2 may play a significant role in prevention of liver cancer caused by viral cirrhosis. In a 2004 study published in the Journal of the American Medical Association, 40 women diagnosed with viral liver cirrhosis were studied, in which 21 were given 45 mg vitamin K2 per day. Vitamin K2 was found to decrease the risk of the development of liver cancer in female patients with viral cirrhosis, possibly by delaying the onset of the cancer. 34 For over seven years, the patient's progress was closely followed. The proportion of patients who developed liver cancer was significantly smaller in the group of women treated with the vitamin K2 (2 of 21), compared to the non-treated group (9 of 19). The annual incidence of liver cancer in the treated group was 1.6%, compared to the non-treated group, which was 8.8%. The researchers believe that a substance called geranyl-geraniol (a by-product of vitamin K2), induces cell death in tumor cells suggesting that it may play an important role in cell growth inhibition. The researchers wrote, "The study indicates that vitamin K2 decreases the risk of liver cancer to about 20% compared to the control group." The researchers also commented that these are only preliminary results and further research needs to be done through clinical trials.

Proudly Made in the USA!

Every LifeSource Vitamins product exceeds all regulation standards and requirements set forth in the FDA's Code of Federal Regulation. ( 21 CFR, part 111 ) as well as all Good Manufacturing Practices enforced by the FDA. CGMP's provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities. ( CGMP ).

LifeSource Vitamins: Driven by Faith ~ Powered by God

Have Questions on this or any other product or health issue for you or a loved one? It can be overwhelming we know. Call us, we will walk you through what supplements will help you and which ones you really don’t need. It’s what we do! Toll-Free: 800-567-8122

LifeSource Vitamins – Founded in 1992

100% of our profits are donated to Christian Organizations like these and many others worldwide:

Campus Crusade for Christ - CRU

The Jesus Film Project

World Vision

The Tim Tebow Foundation

Compassion International

Samaritan’s Purse

The Herman and Sharron Show on CTN (Christian Television Network) and many more…

www.LifesourceVitamins.com

E-mail Us: [email protected]

or Call Us: 800.567.8122

We Are Built on Compassion - Driven by Faith & Powered by God!

*Disclaimer: None of the above statements have been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. As always, consult your physician before taking any and all supplements. LifeSource Vitamins. Individual results may vary.

Disclaimer: All the information contained throughout this website is based upon the opinions of the founder of LifeSource Vitamins, Bruce Brightman, and the entire team at LifeSource Vitamins whose relentless research and studies have been ongoing since 1992. Other articles and information are based on the opinions of the authors, who retain the copyright as marked in the article. The information on this site is not intended to replace your health care professional, but to enhance your relationship with them. Doing your own studying and research and taking your health care into your own hands is always best, especially in partnership with your health care professional.

If you are pregnant, nursing, taking medications, or have any medical conditions, always consult your health care professional before taking supplements based on the information on this site.

LifeSource Vitamins: from the nutrients we choose, to the way we run our business, we answer to God in all we do!

Vitamin K2 References:

1. Schurgers LJ, Vermeer C. Differential lipoprotein transport pathways of K-vitamins in healthy subjects. Biochim Biophys Acta. 2002 Feb 15;1570(1):27-32.

2. Kelleys Textbook of Internal Medicine, Fourth Edition, 2000, Lippincott, Williams and Wilkins, Philadelphia, PA.

3. Knapen MH, Jie KS, Hamulyak K, Vermeer C. Vitamin K-induced changes in markers for osteoblast activity and urinary calcium loss. Calcif Tissue Int. 1993 Aug;53(2):81-5.

4. Booth SL, Sokoll LJ, O'Brien ME, Tucker K, Dawson-Hughes B, Sadowski JA. Assessment of dietary phylloquinone intake and vitamin K status in postmenopausal women. Eur J Clin Nutr. 1995 Nov;49(11):832-41.

5. Vermeer C, Braam L, Schurgers L, Brouns F. Agro-Food Industry Hi-Tech 2002, 13:11-15.

6. Hart JP, Catterall A, Dodds RA, Klenerman L, Shearer MJ, Bitensky L, Chayen J. Lancet ii 283 (1984).

7. Hart JP, Shearer MJ, Klenerman L, Catterall A, Reeve J, Sambrook PN, Dodds RA, Bitensky L, Chayen J. Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis. J Clin Endocrinol Metab. 1985 Jun;60(6):1268-9.

8. Hodges SJ, Pilkington MJ, Stamp TC, Catterall A, Shearer MJ, Bitensky L, Chayen J. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone. 1991;12(6):387-9.

9. Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res. 1993 Oct;8(10):1241-5.

10. Booth SL, Pennington JA, Sadowski JA. Food sources and dietary intakes of vitamin K-1 (phylloquinone) in the American diet: data from the FDA Total Diet Study. J Am Diet Assoc. 1996 Feb;96(2):149-54.

11. Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K. J Nutr. 1998 May;128(5):785-8.

12. Thane CW, Paul AA, Bates CJ, Bolton-Smith C, Prentice A, Shearer MJ. Intake and sources of phylloquinone (vitamin K1): variation with socio-demographic and lifestyle factors in a national sample of British elderly people. Br J Nutr. 2002 Jun;87(6):605-13.

13. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr. 1999 Jan;69(1):74-9.

14. Booth SL, Broe KE, Gagnon DR, Tucker KL, Hannan MT, McLean RR, Dawson-Hughes B, Wilson PW, Cupples LA, Kiel DP. Vitamin K intake and bone mineral density in women and men. Am J Clin Nutr. 2003 Feb;77(2):512-6.

15. Booth SL, Tucker KL, Chen H, Hannan MT, Gagnon DR, Cupples LA, Wilson PW, Ordovas J, Schaefer EJ, Dawson-Hughes B, Kiel DP. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr. 2000 May;71(5):1201-8.

16. Braam LAJLM, Knapen MHJ, Geusens P, Brouns F, Hamulyak K, Gerichhausen MJW, Vermeer C. Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif. Tissue Int. 72, epub (2003).

17. Bolton-Smith C, Mole PA, McMurdo MET, Paterson CR, Shearer MJ. Ann. Nutr. Metab. 45 Suppl. 1 246 (2001).

18. Orimo H, Shiraki M, Tomita A, Morii H, Fujita T, Ohata M. J. Bone Miner. Metab. 16:106-112, 1998.

19. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000 Mar;15(3):515-21.

20. Iwamoto J, Takeda T, Ichimura S. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J Orthop Sci. 2001;6(6):487-92.

21. Jie KS, Bots ML, Vermeer C, Witteman JC, Grobbee DE. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. Atherosclerosis. 1995 Jul;116(1):117-23.

22. Geleijnse JM, Vermeer C, Schurgers LJ, Grobbee DE, Pols HAP, Witteman JCM. Thromb. Haemostas. (Suppl July) P473, 2001.

23. Kawashima H, Nakajima Y, Matubara Y, Nakanowatari J, Fukuta T, Mizuno S, Takahashi S, Tajima T, Nakamura T. Effects of vitamin K2 (menatetrenone) on atherosclerosis and blood coagulation in hypercholesterolemic rabbits. Jpn J Pharmacol. 1997 Oct;75(2):135-43.

24. Spronk HM, Soute BA, Schurgers LJ, Thijssen HH, De Mey JG, Vermeer C. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res. 2003 Nov-Dec;40(6):531-7. Epub 2003 Dec 3.

25. Braam LAJLM. Thesis, Maastricht ISBN 90-5681-145-2, 2002.

26. Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis. 2000 Nov-Dec;30(6):298-307.

27. Ronden JE, Drittij-Reijnders MJ, Vermeer C, Thijssen HH. Intestinal flora is not an intermediate in the phylloquinone-menaquinone-4 conversion in the rat. Biochim Biophys Acta. 1998 Jan 8;1379(1):69-75.

28. Vermeer C, Braam L, Knapen M and Schurgers L; Vitamin K supplementation: a simple way to improve vascular health. Agr Food Industry hi Tech Nov 2003.

29. Vermeer C, Shearer MJ, Zittermann A, Bolton-Smith C, Szulc P, Hodges S, Walter P, Rambeck W, Stocklin E, Weber P. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr. 2004 Dec;43(6):325-35. Epub 2004 Feb 5.

30. Schurgers LJ. Thesis, Maastricht ISBN 90-5681-138-X, 2002.

31. Sakamoto N, Wakabayashi I, Sakamoto K. Low vitamin K intake effects on glucose tolerance in rats. Int J Vitam Nutr Res. 1999 Jan;69(1):27-31.

32. Mukai K, Itoh S, Morimoto H. Stopped-flow kinetic study of vitamin E regeneration reaction with biological hydroquinones (reduced forms of ubiquinone, vitamin K, and tocopherolquinone) in solution. J Biol Chem. 1992 Nov 5;267(31):22277-81.

33. Mukai K, Morimoto H, Kikuchi S, Nagaoka S. Kinetic study of free-radical-scavenging action of biological hydroquinones (reduced forms of ubiquinone, vitamin K and tocopherol quinone) in solution. Biochim Biophys Acta. 1993 Jul 11;1157(3):313-7.

34. Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, Nishiguchi S. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA, 2004 Jul 21;292(3):358-61.